Ceramedix Holding develops antibody-based therapeutics targeting novel diseases through advanced biotherapeutic techniques. The company focuses on creating effective treatments for conditions that currently lack adequate medical solutions.
Funding
$3M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Microvascular injury, driven by ceramide-rich platforms, contributes to the pathology of several diseases, including early-onset Diabetic Retinopathy/Diabetic Macular Edema, for which current treatments are inadequate or require invasive procedures. Addressing the root cause of these diseases is critical for effective intervention and improved patient outcomes.
Solution
Ceramedix is developing first-in-class antibody therapeutics that target ceramide-rich platforms to reverse microvascular injury and treat related diseases. Their lead program focuses on a treatment for early-onset Diabetic Retinopathy/Diabetic Macular Edema, designed to enable early pharmacologic intervention. The antibodies selectively disrupt ceramide-rich platforms, addressing the underlying cause of the disease. The therapy is administered subcutaneously, eliminating the need for intravitreal injections. This approach aims to transform patient care by providing a less invasive and more effective treatment option.
Target Audience
The primary target audience includes patients with early-onset Diabetic Retinopathy/Diabetic Macular Edema, as well as healthcare providers specializing in ophthalmology and seeking novel therapeutic options.
Features
- Proprietary anti-ceramide antibodies designed to disrupt ceramide-rich platforms
- Subcutaneous administration, avoiding invasive intravitreal injections
- Focus on addressing the root cause of microvascular injury in diseases like Diabetic Retinopathy
- Potential for early pharmacologic intervention to prevent disease progression